Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The FIRST-2.0 China study, officially titled “Finerenone FIRST (Finerenone Research of Early Safety and Effectiveness), Part 2.0 in China,” tracks how Bayer’s finerenone is used in everyday care for people in China with chronic kidney disease and type 2 diabetes. It focuses on real-world safety and effectiveness, which helps bridge the gap between controlled trials and daily clinical practice.
The treatment under review is finerenone, marketed as Kerendia and developed by Bayer. It is a drug designed to protect kidney function and reduce complications in patients with chronic kidney disease linked to type 2 diabetes.
This is an observational, retrospective cohort study, meaning doctors do not assign treatments, but researchers analyze existing patient records. There is no blinding or randomization; the aim is to understand patterns of real-life use, safety issues, and treatment outcomes rather than to test a new regimen against a control.
The study uses data from the Tianjin Healthcare and Medical Big Data Platform, which covers about 15 million residents, to follow patients who start finerenone. Researchers look at kidney markers, such as filtration rate and urinary protein, as well as potassium levels, hospitalizations for high potassium, and dose adjustments over time.
Key timing signals for investors include the completed overall status and the latest update filed on April 12, 2026, which confirms that Bayer has wrapped up data gathering and is refining analyses. Earlier milestones include the initial submission on August 8, 2025, and ongoing work toward first public results, which are likely to follow this latest data refresh.
For Bayer (BAYRY), positive real-world safety and effectiveness data in a large Chinese population could support wider physician adoption of finerenone and bolster long-term revenue in kidney and diabetes care. It also helps Bayer defend share against rival kidney-protective drugs from companies such as AstraZeneca and Novo Nordisk, and may lift sentiment toward the company’s cardiovascular and renal portfolio.
The FIRST-2.0 China study has completed data collection and remains in analysis and reporting, with further details available on the ClinicalTrials portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.